# PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD

> **NCT04543812** · PHASE3 · COMPLETED · sponsor: **Panion & BF Biotech Inc.** · enrollment: 141 (actual)

## Conditions studied

- Anemia of Chronic Kidney Disease

## Interventions

- **DRUG:** Ferric citrate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04543812
- **Lead sponsor:** Panion & BF Biotech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-14
- **Primary completion:** 2022-10-28
- **Final completion:** 2022-12-16
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04543812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04543812, "PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04543812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*